Long-term Evaluation of Quality of Life and Aesthetic Outcomes After Autologous Breast Reconstruction Using the Profunda Artery Perforator (PAP) Flap

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

Breast reconstruction using autologous tissue is an important option for women undergoing mastectomy for breast cancer. The profunda artery perforator (PAP) flap is a reliable alternative when abdominal tissue is unavailable or unsuitable for reconstruction. Although the PAP flap is increasingly used, limited data are available regarding long-term patient-reported quality of life, aesthetic outcomes, and donor-site morbidity.

This monocentric observational study aims to evaluate long-term quality of life in women who underwent breast reconstruction with a PAP flap at the European Georges Pompidou Hospital between 2014 and 2024. Participants will complete validated patient-reported outcome questionnaires (BREAST-Q Reconstruction Module and PROMIS-29) and undergo a standardized clinical and photographic assessment. Aesthetic outcomes will be evaluated using objective photographic analysis and blinded expert review.

The study will provide comprehensive information on patient satisfaction, functional outcomes, aesthetic results, and donor-site sequelae following PAP flap breast reconstruction.

Eligibility criteria

Qualifiers

Female patients aged 18 years or older.

History of unilateral or bilateral breast reconstruction using a profunda artery perforator (PAP) flap.

Breast reconstruction performed between 2014 and 2024 at the European Georges Pompidou Hospital.

Able to understand study procedures and complete study questionnaires.

Disqualifiers

Patients younger than 18 years.

Breast reconstruction performed using techniques other than PAP flap.

Breast reconstruction performed outside the study period (2014-2024).

Patients under legal protection measures.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

264 Participants
are grouped into 1 trial group